Citations

Showing 10 of 108094 citations.

Cytotechnologists as coinvestigators in anatomical pathology research
Kopp, Karla, Passow, Marie R. , Rosario, Kristina M Del, Christensen, Michael R , O’Shaughnessy, John W., Bartholet, Mary, Francis, Mary E., Flotte, Thomas J. , Kopp, Karla J, Del Rosario, Kristina M, Bartholet, Mary K, Flotte, Thomas James

Mayo Clinic

Cancer Cytopathology | January 10, 2018 | Volume: 126 | Issue: 4 | Pages: 232-235

10.1002/cncy.21968 | PMID 29316317 Get It

BACKGROUNDThe amount of time available to pathologists with which to perform research is becoming limited due to an increasing manpower shortage in pathology, decreased reimbursement, and increased workload. This is occurring at the same time as demands escalate for pathologists to develop new companion tests, correlate the molecular findings with traditional methods, and assist in the development of individualized medicine. This study examined whether cytotechnologists may be integrated into a research team that uses their expertise in understanding pathology and clinical disease to provide interpretations of experiments that traditionally were performed by pathologists.METHODSCytotechnologists worked with pathologists to choose blocks for tissue microarrays (TMAs) and to interpret immunohistochemically stained TMA slides. The pathologist met with the cytotechnologist to review the study design. The cytotechnologists reviewed the slides and blocks and chose the most appropriate blocks for the TMA. Either 10% or all of the slides/blocks selected for TMA construction were reviewed by the supervising pathologist. The final selections were given to the TMA technologist to make the TMA. A minimum of 10% of the immunohistochemically stained TMA slides were reviewed by the supervising pathologist.RESULTSA total of 32 TMAs were created with 6 cytotechnologists collaborating with 6 pathologists. Immunohistochemical stains of 190 TMAs were interpreted by 4 cytotechnologists collaborating with 3 pathologists. All the TMAs and TMA interpretation data were used successfully for the research for which they were designed.CONCLUSIONSThe collaboration of cytotechnologists and pathologists in research can improve the quality of effort and increase satisfaction and productivity. Cancer Cytopathol 2018;126:232‐5. © 2018 American Cancer Society.
Testicular plasmacytoma: unique location or circumstantial presentation?
Muchtar, Eli , Bladé, Joan , Gertz, Morie A. , Gertz, Morie A , Muchtar, E

Mayo Clinic

Leukemia & Lymphoma | January 10, 2018 | Volume: 59 | Issue: 8 | Pages: 1769-1771

10.1080/10428194.2017.1421763 | PMID 29316841 Get It

Hypertrophic obstructive cardiomyopathy: what, when, why, for whom?
Bartel, Thomas , Sorgente, Antonio, Müller, Silvana, Gruner, Christiane, Quintana, Eduard , Dearani, Joseph, Mestres, Carlos A. , Sorgente, Antonio, Dearani, Joseph A.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | January 10, 2018 | Volume: 53 | Issue: 4 | Pages: 700-707

10.1093/ejcts/ezy020 | PMID 29438530 Get It

Arrhythmia after cone repair for Ebstein anomaly: The Mayo Clinic experience in 143 young patients
Wackel, Philip L. , Cannon, Bryan C. , Dearani, Joseph A. , Sessions, Kristen L., Holst, Kimberly , Johnson, Jonathan N. , Cetta, Frank , Wackel, Philip , Cannon, Bryan, Dearani, Joseph, Sessions, Kristen, Johnson, Jonathan , Dearani, Joseph A.

Mayo Clinic

Congenital Heart Disease | January 10, 2018 | Volume: 13 | Issue: 1 | Pages: 26-30

10.1111/chd.12566 | PMID 29316261 Get It

NACSELD acute‐on‐chronic liver failure (NACSELD‐ACLF) score predicts 30‐day survival in hospitalized patients with cirrhosis
O’Leary, Jacqueline G. , Reddy, K. Rajender , García–Tsao, Guadalupe , Biggins, Scott W. , Fallon, Michael B. , Subramanian, Ram, Kamath, Patrick S. , Thuluvath, Paul J. , Vargas, Hugo E. , Maliakkal, Benedict, Bajaj, Jasmohan S. , Tandon, Puneeta , Bajaj, Jasmohan S , Vargas, Hugo E , Wong, Florence , Tandon, Puneeta , Lai, Jennifer C. , Thacker, Leroy R.

Mayo Clinic

Hepatology | January 10, 2018 | Volume: 67 | Issue: 6 | Pages: 2367-2374

10.1002/hep.29773 | PMID 29315693 Get It

The North American Consortium for the Study of End‐Stage Liver Disease's definition of acute‐on‐chronic liver failure (NACSELD‐ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD‐ACLF's ability to predict 30‐day survival (defined as in‐hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60%/40% into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79%) men (62%) with a mean age of 57 years and a diagnosis of alcohol‐induced cirrhosis (45%), and 1,079 patients had an infection during hospitalization. The mean Model for End‐Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD‐ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End‐Stage Liver Disease score, and presence of infection. The c‐statistics were 0.8073 for the training set and 0.8532 for the validation set. Conclusion: Although infection status remains an important predictor of death, NACSELD‐ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30‐day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (H epatology 2018;67:2367‐2374).
Deletion of endoplasmic reticulum stress‐responsive co‐chaperone p58IPK protects mice from diet‐induced steatohepatitis
Bandla, Harikrishna, Dasgupta, Debanjali , Mauer, Amy S. , Nožičková, Barbora, Kumar, Swarup , Graham, Rondell P. , Malhi, Harmeet , Graham, Rondell P , Hirsova, Petra , Dasgupta, Debanjali

Mayo Clinic

Hepatology Research | January 10, 2018 | Volume: 48 | Issue: 6 | Pages: 479-494

10.1111/hepr.13052 | PMID 29316085 Get It

AimActivation of PKR‐like endoplasmic reticulum kinase (PERK), an endoplasmic reticulum stress sensor, is a feature of non‐alcoholic steatohepatitis (NASH), yet regulators of PERK signaling remain undefined in this context. The protein p58IPK regulates PERK; however, its role in NASH has not been examined. The aim of this study was to assess the in vivo role of p58IPK in the pathogenesis of dietary NASH.MethodsParameters of hepatocyte cell death, liver injury, inflammation, fibrosis, indirect calorimetry and PERK activation were assessed in p58IPK knockout (p58ipk−/−) mice and their wild‐type littermate controls. All animals were fed a diet enriched in fat, fructose, and cholesterol (FFC) for 20 weeks.ResultsActivation of PERK was attenuated in FFC‐fed p58ipk−/− mice. Accordingly, FFC‐fed p58ipk−/− mice showed a reduction in hepatocyte apoptosis and death receptor expression, with a significant reduction in serum alanine transaminase values. Correspondingly, macrophage accumulation and fibrosis were significantly lower in FFC‐fed p58ipk−/− mice.ConclusionWe have shown that, in an in vivo dietary NASH model, p58IPK mediates hepatocyte apoptosis and liver injury, likely through PERK phosphorylation. In the absence of p58IPK, PERK phosphorylation and NASH are attenuated. Inhibition of hepatic p58IPK could be a future target for NASH therapy.
Skeletal Muscle Compensation for Cardiac Muscle Insufficiency in Heart Failure and Reduced Ejection Fraction
Reddy, Yogesh N.V. , Obokata, Masaru , Haykowsky, Mark J. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation: Heart Failure | January 10, 2018 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.117.004714 | PMID 29317402 Get It

Oversensing of transthoracic excitation stimuli in contemporary pacemakers
Ryan, J. , Tempel, Nathan D., Engle, Dean D., Hayes, David L. , Cha, Yong‐Mei , Asirvatham, Samuel J. , Ryan, James D , Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | January 10, 2018 | Volume: 41 | Issue: 2 | Pages: 161-166

10.1111/pace.13269 | PMID 29315719 Get It

AbstractBackgroundTransthoracic impedance measurements (TIM) is primarily used for minute ventilation rate adaptive sensors in pacemakers. With elevated impedance, the TIM electrical signal itself is oversensed, causing device malfunction.ObjectiveWe report an increased incidence of TIM oversensing.MethodRetrospective chart review. We review existing records of 18 patients who have demonstrated device malfunction with TIM oversensing.ResultsWe have found a 1.8% incidence of TIM‐related oversensing in our patient population of 959 patients with contemporary Boston Scientific (Marlborough, MA, USA) pacemakers and cardiac resynchronization therapy pacemakers. One patient experienced a syncopal episode.ConclusionOversensing with pacing inhibition is apparent with the potential of adverse effects to patients.
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia
Mangaonkar, Abhishek A. , Hoversten, Katherine P., Gangat, Naseema

Mayo Clinic

Expert Review of Hematology | January 10, 2018 | Volume: 11 | Issue: 3 | Pages: 247-252

10.1080/17474086.2018.1426455 | PMID 29313725 Get It

Reply to Castillo et al.
Abeykoon, Jithma P. , King, Rebecca L. , Ansell, Stephen M., Paludo, Jonas , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Rajkumar, S. Vincent , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | January 9, 2018 | Volume: 93 | Issue: 3 | Pages: No page available

10.1002/ajh.25029 | PMID 29314230 Get It